Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75874

UPID:
IDHC_HUMAN

ALTERNATIVE NAMES:
Cytosolic NADP-isocitrate dehydrogenase; IDPc; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase

ALTERNATIVE UPACC:
O75874; Q567U4; Q6FHQ6; Q7Z3V0; Q93090; Q9NTJ9; Q9UKW8

BACKGROUND:
The cytoplasmic enzyme Isocitrate dehydrogenase [NADP] (IDH), also known as IDPc, plays a crucial role in the citric acid cycle by converting isocitrate to 2-ketoglutarate. This reaction is essential for the generation of NADPH, which is crucial for numerous biosynthesis pathways. IDH also contributes to corneal epithelial health by maintaining transparency.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Isocitrate dehydrogenase [NADP] cytoplasmic could open doors to potential therapeutic strategies. Its involvement in glioma through specific mutations that lead to abnormal metabolite production highlights its significance in cancer research. Therapeutic interventions targeting these mutations could revolutionize treatment paradigms for gliomas.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.